warned investors Friday that its third-quarter revenue will be lower than had been expected.
However, the company reiterated its full-year top line estimate of more than $200 million, thanks to 20% to 25% growth in prescriptions of its immune system-suppressing drug CellCept.
Still, stockholders were focused on the warning, and Aspreva's shares slid 9.6% to $22.50.
The company expects to report $48 million in revenue for the third quarter, while analysts were calling for about $54.3 million. Aspreva cited the negative impact of foreign-exchange rates and reconciliation payments to
related to a collaboration agreement.